Skip to main content

Advertisement

Log in

Congenital Adrenal Hyperplasia and Growth Outcomes

  • Editorial Commentary
  • Published:
The Indian Journal of Pediatrics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Bonfig W. Growth and development in children with classic congenital adrenal hyperplasia. Curr Opin Endocrinol Diabetes Obes. 2017;24:39–42.

    PubMed  Google Scholar 

  2. Sharma R, Seth A. Congenital adrenal hyperplasia: issues in diagnosis and treatment in children. Indian J Pediatr. 2014;81:178–85.

    Article  PubMed  Google Scholar 

  3. Speiser PW, Arlt W, Auchus RJ, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society Clinical Practice. J Clin Endocrinol Metab. 2018;103:4043–88.

  4. Muthusamy K, Elamin MB, Smushkin G, et al. Clinical review: adult height in patients with congenital adrenal hyperplasia: a systematic review and metaanalysis. J Clin Endocrinol Metab. 2010;95:4161–72.

    Article  CAS  PubMed  Google Scholar 

  5. Balsamo A, Cicognani A, Baldazzi L, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2003;88:5680–8.

    Article  CAS  PubMed  Google Scholar 

  6. Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, Schwarz HP. Hydrocortisone dosing during puberty in patients with classicalcongenital adrenal hyperplasia: an evidence-based recommendation. J Clin Endocrinol Metab. 2009;94:3882–8.

    Article  CAS  PubMed  Google Scholar 

  7. Maheshwari A, Khadilkar V, Gangodkar P, Khadilkar A. Long-term growth in congenital adrenal hyperplasia. Indian J Pediatr. 2018. https://doi.org/10.1007/s12098-018-2753-6.

  8. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler GB Jr. Flutamide, testolactone, and reduced hydrocortisone dose maintain 665 normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab. 2000;85:1114–20.

    Article  CAS  PubMed  Google Scholar 

  9. Verma S, Vanryzin C, Sinaii N, et al. A pharmacokinetic and pharmacodynamic study of delayed and extended-release hydrocortisone (Chronocort) vs. conventional 671 hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol. 2010;72:441–7.

    Article  CAS  Google Scholar 

  10. Lin-Su K, Harbison MD, Lekarev O, Vogiatzi MG, New MI. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. J Clin Endocrinol Metab. 2011;96:1710–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: the ability to achieve normal growth. Pediatrics. 2000;106:767–73.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rajni Sharma.

Ethics declarations

Conflict of Interest

None.

Source of Funding

None.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, R. Congenital Adrenal Hyperplasia and Growth Outcomes. Indian J Pediatr 86, 111–112 (2019). https://doi.org/10.1007/s12098-018-2841-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12098-018-2841-7

Navigation